United States patent law

electroCore Expands Intellectual Patent Portfolio for nVNS Technology

Retrieved on: 
Wednesday, April 12, 2023
Patent, Vagus nerve, United States Patent and Trademark Office, United States patent law, Brain, Dopamine, Disorder, ECOR, US, NVN, ElectroCore, Addiction, Hertz, FDA, Pharmaceutical industry

ROCKAWAY, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).

Key Points: 
  • ROCKAWAY, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).
  • The three patents were issued on April 11, 2023, and relate to the electroCore’s non-invasive vagus nerve stimulation (nVNS) technology, including the following patents:
    US Patent Nos.
  • 11,623,079 and 11,623,080 entitled “Vagal Nerve Stimulation Devices and Methods for Treating Medical Conditions” and “Vagal Nerve Stimulation for Dopamine-Related Conditions,” respectively.
  • “electroCore continues to broaden its intellectual property portfolio, which consists of over 200 patents and patent applications,” stated Dan Goldberger, Chief Executive Officer of electroCore.

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System

Retrieved on: 
Tuesday, April 11, 2023
Patent, Weight loss, Invention, United States patent law, Tensor reshaping, SAN, PTE, Pharmaceutical industry

The patent will cover additional claims for the Obalon® Balloon System and is expected to provide protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).

Key Points: 
  • The patent will cover additional claims for the Obalon® Balloon System and is expected to provide protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).
  • “Allowance of this patent significantly strengthens our intellectual property portfolio around innovations for the Obalon Intragastric Balloon System,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences.
  • “Since filing our first patent application in 2011, ReShape has pioneered the field, amassing a patent family around the intragastric balloon system, supported by a variety of novel, pending and protected inventions.
  • Going forward, we will continue to build a defensive ‘moat’ around our product portfolio and commercialization efforts, while also taking offensive action to defend our patent position, when necessary.”

Nox Medical Secures New Patent for Calculating Respiratory Effort During Sleep Studies

Retrieved on: 
Wednesday, April 5, 2023
Patent, Classification, RIP, EVP, Respiration, Sleep, United States patent law, Sleep apnea, United States Patent Office fire, IP, Literature, Patent analysis, Abdomen, AI, Pharmaceutical industry, Nox

US 11,602,282 B2 describes how the signals recorded from Nox standard respiratory effort bands (RIP) can be used to derive information on internal respiratory effort mechanisms.

Key Points: 
  • US 11,602,282 B2 describes how the signals recorded from Nox standard respiratory effort bands (RIP) can be used to derive information on internal respiratory effort mechanisms.
  • This information allows medical providers and sleep scientists to understand what is happening within the body during sleep studies without using invasive measures.
  • This characteristic of the Nox RIP technology allows more information to be extracted from the signals than only the conventional respiratory effort indicators used in standard sleep studies.
  • The new patent is part of a series of patent filings to protect Nox Medical’s intellectual property related to information derived from the Nox RIP technology.

Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office

Retrieved on: 
Tuesday, April 11, 2023
Biotechnology, Pharmaceutical, Health, Patent, MMF, The Orange Book, EGFR, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Orange Book, Patient, Lupus nephritis, FDA, United States patent law, Pharmaceutical industry, Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the United States Patent and Trademark Office (USPTO) has issued a new and refined method of use patent titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the United States Patent and Trademark Office (USPTO) has issued a new and refined method of use patent titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS.
  • The newly issued patent provides coverage that supplements Aurinia’s existing U.S. Patent No.
  • The claims in this additional patent add further specificity on dosing consistent with the FDA approved product label.
  • This patent has the potential to provide an additional layer of patent protection for LUPKYNIS up to 2037.

Applied Information Granted Patent to Streamline Data and Reduce Bandwidth for Cellular Vehicle to Everything Communications up to 97%

Retrieved on: 
Wednesday, April 5, 2023
Other Transport, Apps, Applications, Technology, Mobile, Wireless, Automotive, General Automotive, Vehicle Technology, Transport, Networks, Applied Information Science in Economics, Communication, Information, Patent, 2600-series (CTA), United States patent law, Receiver, Mobile phone

Applied Information, Inc ., the leading provider of intelligent transportation infrastructure technology, announced today that the U.S. Patent and Trademark Office has granted the company a patent covering its Connected Vehicle computing and communications method that significantly reduces the amount of bandwidth needed for traffic signals and other traffic control devices to communicate with vehicles.

Key Points: 
  • Applied Information, Inc ., the leading provider of intelligent transportation infrastructure technology, announced today that the U.S. Patent and Trademark Office has granted the company a patent covering its Connected Vehicle computing and communications method that significantly reduces the amount of bandwidth needed for traffic signals and other traffic control devices to communicate with vehicles.
  • U.S. Patent 11,594,127 entitled Systems, Methods, and Devices for Communication Between Traffic Controller Systems and Mobile Transmitters and Receivers describes a system that sends real-time, connected vehicle messages from a traffic signal or other traffic control over the C-V2X Network (Uu) or C-V2X Direct (PC5).
  • The technology enables a reduction of bandwidth usage by up to 97 percent.
  • Traffic control devices equipped with Applied Information’s technology send messages to nearby connected vehicles only as necessary and when there is a change of status – such as a traffic signal changing from red to green, thereby significantly reducing the amount of data.

Novo Integrated Sciences Reports Fiscal Full Year 2022 Financial Results

Retrieved on: 
Monday, April 3, 2023
Alternative Medicine, Health, Telemedicine, Virtual Medicine, Other Health, Managed Care, Biotechnology, LA Fitness, Iodine, American University of Integrative Sciences, Patent, Telehealth, NPN, Acquisition, Novo, Diagnosis, Natural product, FDA, Health Canada, United States patent law, Fiscal, Pharmaceutical industry, Cryptocurrency, Property management

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, today reported its financial results for the fiscal year ended August 31, 2022.

Key Points: 
  • Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, today reported its financial results for the fiscal year ended August 31, 2022.
  • Revenues for the year ended August 31, 2022 were $11,737,937, representing an increase of $2,432,682, or 26%, from $9,305,255 for the same period in 2021.
  • Net loss attributed to Novo Integrated Sciences for the year ended August 31, 2022 was $32,849,215, representing an increase of $28,387,068, or 636%, from $4,462,147 for the same period in 2021.
  • Subsequent to the end of fiscal year 2022, the second of two $1.875m notes was paid in full.

Microbion Corp. Granted US Patent for the Use of Inhaled Pravibismane for Pulmonary Infections

Retrieved on: 
Tuesday, April 4, 2023
Bismuth, GLP, Patent, QIDP, Infection, United States Patent and Trademark Office, United States patent law, US, Work, Patient, Cystic fibrosis, Pharmaceutical industry

11,464,749 to Microbion with claims to the use of Microbion's proprietary pravibismane inhaled composition for treatment of pulmonary infections.

Key Points: 
  • 11,464,749 to Microbion with claims to the use of Microbion's proprietary pravibismane inhaled composition for treatment of pulmonary infections.
  • The patent, entitled "Bismuth-thiol compositions and methods of use," extends inhaled pravibismane patent protection through mid-2039.
  • The granted claims cover the administration and use of inhaled pravibismane compositions in pulmonary infections.
  • This patent further expands Microbion's patent portfolio, comprising granted claims to its pravibismane composition and methods of treating infections of the respiratory tract.

Greenway Technologies Announces New Additions to G-Reformer™ Technology Patent Portfolio

Retrieved on: 
Wednesday, March 29, 2023
Hexane, Patent, Petroleum, Moses Austin, University, Ethanol, United States Patent and Trademark Office, Oxygen, Methanol, United States patent law, OTCQB, GTL, Octane, Fischer–Tropsch process, Heptane, Steam, Natural gas, Methane, Coal, TEXAS

These two new patents are the latest addition to Greenway’s portfolio of issued patents and pending patent applications owned or licensed by Greenway and covering the G-ReformerTM technology and other technologies related to GTL processes.

Key Points: 
  • These two new patents are the latest addition to Greenway’s portfolio of issued patents and pending patent applications owned or licensed by Greenway and covering the G-ReformerTM technology and other technologies related to GTL processes.
  • 11,453,827 issued on September 27, 2022, and United States Patent No.
  • These are the fifth and sixth granted patents relating to the G-ReformerTM technology.
  • We believe that this technology will ultimately be used to provide incrementally cleaner fuels while minimizing the environmental impact, consistent with worldwide green initiatives.”
    AdamsIP, LLC represented Greenway in prosecuting the above patents before the United States Patent and Trademark Office.

REGIONAL CHARITY OBTAINS SERVICE MARK REGISTRATION

Retrieved on: 
Wednesday, March 29, 2023
Manna, Edible, Patent, Organic, Food, Bible, Service mark, Registered trademark symbol, TM, Woman, United States patent law, Platinum, Organization, Name, United Kingdom trade mark law, Family, Grocery store, LinkedIn

DERWOOD, Md., March 29, 2023 /PRNewswire/ -- Celestial Manna®, one of the oldest food rescue charities in Maryland, has something new on its website.  Earlier this year, the US Patent and Trademark Office (USPTO) recognized the unique standing of this 37-year-old charity by granting a Trade Mark on the name, and a Service Mark on the symbol. Written as the letters TM inside a circle, a Registered Trademark designation indicates uniqueness in the marketplace and helps protect the organization from impersonation.

Key Points: 
  • Earlier this year, the US Patent and Trademark Office (USPTO) recognized the unique standing of this 37-year-old charity by granting a Trade Mark on the name, and a Service Mark on the symbol.
  • A trademark can be any name, word, symbol, slogan, or device that identifies and distinguishes a business or product from others in the market.
  • Celestial Manna took this step to distinguish itself from other charities in the region that also have the word Manna in their name.
  • The logo is also now protected with a similar protection, called a Service Mark.

Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, March 27, 2023
Society, Epilepsy, Food and Drug Administration, Prescription, MSUD, Acquisition, Patent, Patient, Menopause, Collaboration, Celiprolol, Diet, VMS, Contra, Syndrome, UCD, PCDC, Sodium benzoate, Ammonia, CPS, FDA, Body surface area, Maple syrup urine disease, BSA, Liver, SIMD, Hot, Maharishi Sandipani Rashtriya Ved Vidya Pratishthan, Annual report, Blood, ACER, Research, Therapy, Medicaid, Information technology, Clinical trial, United States patent law, Woman, Urea, Sale, State Administrative Expenses, UCD School of Medicine, OTC, Annual general meeting, Food, Pharmaceutical industry, Cryptocurrency, Maple syrup, Acer, Discover

OLPRUVA™ is not used to treat rapid increase of ammonia in the blood (acute hyperammonemia), which can be life-threatening and requires emergency medical treatment.

Key Points: 
  • OLPRUVA™ is not used to treat rapid increase of ammonia in the blood (acute hyperammonemia), which can be life-threatening and requires emergency medical treatment.
  • As a result, Acer is pausing the ACER-801 program until Acer has conducted a thorough review of the full data set
    Ended Q4 2022 with $2.3 million in cash and cash equivalents.
  • Cash and cash equivalents were $2.3 million as of December 31, 2022, compared to $12.7 million as of December 31, 2021.
  • For additional information, please see Acer’s Annual Report on Form 10-K filed today with the SEC.